Revenue - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details) - USD ($) $ in Millions	Dec. 12, 2021	Dec. 21, 2021
Allocation Of Transaction Price [Abstract]
Deferred revenues as of 12/21/2021		$ 165
Option payment for Domvanalimab	$ 275
Option payment for Etrumadenant	250
Option payment for Quemliclustat	200
Total transaction price	890
Revenue, Performance Obligation [Abstract]
Domvanalimab license	329
Domvanalimab - R&D services	34
Etrumadenant - License and R&D services	219
Quemliclustat - License and R&D services	176
Zimberelimab - R&D and commercial services	11
Access rights	84
Option continuation periods	37
Total allocated transaction price	$ 890